ATLAS-2M, Wk 96 Results: Long-Acting Injectable Cabotegravir + Rilpivirine Every 8 Wks Is Noninferior to Every 4 Wks

Source: 2021 Conference on Retroviruses and Opportunistic Infections*
Download Slideset
March 6-10, 2021; Virtual
Long-acting cabotegravir plus rilpivirine injections every 2 months are noninferior to monthly injections at Week 96 in virologically suppressed patients with no prior virologic failure.
Format: Microsoft PowerPoint (.ppt)
File Size: 172 KB
Released: March 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Download CCO slides reviewing clinically relevant new data reported at CROI 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Released: April 9, 2021

CCO commentary by Daniel R. Kuritzkes, MD, on emerging HIV treatment option data presented at CROI 2021

Daniel R. Kuritzkes, MD Released: April 6, 2021

CCO expert commentary by Dr. Darrell Tan on long-acting ART data presented at CROI 2021 and implications for clinical practice

person default Darrell H. S. Tan, MD, FRCPC, PhD Released: April 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue